From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer's disease treatment

Artur Galushkin; Illana Gozes

doi:10.1016/j.crbiot.2024.100254

From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer's disease treatment

Artur Galushkin, Illana Gozes^*

^*Corresponding author for this work

Human Molecular Genetics Biochemistry

Research output: Contribution to journal › Review article › peer-review

Abstract

Alzheimer's Disease (AD) represents a significant neurodegenerative challenge with current therapeutic strategies primarily focused on symptomatic management. This review explores the relationship between disrupted circadian rhythms, AD and the critical involvement of vasoactive intestinal peptide (VIP) and adenylate cyclase-activating polypeptide (PACAP) signaling pathways. These pathways hold promise for new drug development and provide insights into the complex pathogenesis of AD. Enhancement of brain bioavailability through advanced drug delivery systems is proposed and reviewed.

Original language	English
Article number	100254
Journal	Current Research in Biotechnology
Volume	8
DOIs	https://doi.org/10.1016/j.crbiot.2024.100254
State	Published - Jan 2024

Keywords

ADNP
Alzheimer's Disease
Circadian Clock
PACAP
Tauopathy
VIP

Access to Document

10.1016/j.crbiot.2024.100254

Cite this

@article{e5dfbabc33bb4a648a1f07dd8fa85dd8,

title = "From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer's disease treatment",

abstract = "Alzheimer's Disease (AD) represents a significant neurodegenerative challenge with current therapeutic strategies primarily focused on symptomatic management. This review explores the relationship between disrupted circadian rhythms, AD and the critical involvement of vasoactive intestinal peptide (VIP) and adenylate cyclase-activating polypeptide (PACAP) signaling pathways. These pathways hold promise for new drug development and provide insights into the complex pathogenesis of AD. Enhancement of brain bioavailability through advanced drug delivery systems is proposed and reviewed.",

keywords = "ADNP, Alzheimer's Disease, Circadian Clock, PACAP, Tauopathy, VIP",

author = "Artur Galushkin and Illana Gozes",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = jan,

doi = "10.1016/j.crbiot.2024.100254",

language = "אנגלית",

volume = "8",

journal = "Current Research in Biotechnology",

issn = "2590-2628",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - From circadian sleep disruption to Neuroprotection

T2 - The potential of VIP/PACAP in Alzheimer's disease treatment

AU - Galushkin, Artur

AU - Gozes, Illana

PY - 2024/1

Y1 - 2024/1

N2 - Alzheimer's Disease (AD) represents a significant neurodegenerative challenge with current therapeutic strategies primarily focused on symptomatic management. This review explores the relationship between disrupted circadian rhythms, AD and the critical involvement of vasoactive intestinal peptide (VIP) and adenylate cyclase-activating polypeptide (PACAP) signaling pathways. These pathways hold promise for new drug development and provide insights into the complex pathogenesis of AD. Enhancement of brain bioavailability through advanced drug delivery systems is proposed and reviewed.

AB - Alzheimer's Disease (AD) represents a significant neurodegenerative challenge with current therapeutic strategies primarily focused on symptomatic management. This review explores the relationship between disrupted circadian rhythms, AD and the critical involvement of vasoactive intestinal peptide (VIP) and adenylate cyclase-activating polypeptide (PACAP) signaling pathways. These pathways hold promise for new drug development and provide insights into the complex pathogenesis of AD. Enhancement of brain bioavailability through advanced drug delivery systems is proposed and reviewed.

KW - ADNP

KW - Alzheimer's Disease

KW - Circadian Clock

KW - PACAP

KW - Tauopathy

KW - VIP

UR - http://www.scopus.com/inward/record.url?scp=85203652845&partnerID=8YFLogxK

U2 - 10.1016/j.crbiot.2024.100254

DO - 10.1016/j.crbiot.2024.100254

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:85203652845

SN - 2590-2628

VL - 8

JO - Current Research in Biotechnology

JF - Current Research in Biotechnology

M1 - 100254

ER -

From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer's disease treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this